Abstract
The availability of safe replacement clotting factor concentrates together with effective antiviral drugs to treat human immunodeficiency and hepatitis C viruses and the provision of care at designated haemophilia treatment centres have resulted in a new phenomenon in haemophilia management - the ageing patient. Today, increasing numbers of persons with haemophilia (PWH) are middle-aged and older, and they face the same age-related health issues as the general population. The impact of these risks on PWH is unclear, however, and there is a paucity of information about how to manage comorbidities in this patient population. This review focuses on five comorbidities that uniquely affect older PWH: cardiovascular disease, liver disease, cancer, renal disease and joint disease. Available research is summarized and potential management approaches are suggested.
Original language | English (US) |
---|---|
Pages (from-to) | 1197-1209 |
Number of pages | 13 |
Journal | Haemophilia |
Volume | 15 |
Issue number | 6 |
DOIs | |
State | Published - Nov 2009 |
Keywords
- Ageing
- Comorbidities
- Haemophilia
ASJC Scopus subject areas
- Genetics(clinical)
- Hematology